Professional background

Current posts:

  • Dean, Faculty of Medical Sciences, University College London (August 2015-date)
  • Professor of interventional oncology, Division of Surgery and Interventional Science, UCL
  • Honorary consultant urologist, UCLH (1998 to date)

Current positions:

  • NIHR senior investigator March 2015 – to date
  • British Association of Urological Surgeons Research Lead 2014 – to date
  • Founding Pioneer, Prostate Cancer UK Charity 2013 – to date
  • Macmillan Cancer Care Advisory Board March 2015 – to date
  • Chairman Trial Steering Committee NIHR HTA UpStream Trial August 2014 – to date

Former positions:

  • Director, Division of Surgery and Interventional Science, Royal Free and University College London School of Medicine, University College London (April 2012 – to date)
  • Director, Clinical Trials Unit (Surgery) UCL, London (2013 – Mar 2015)
  • Honorary clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, London (2010 to 2015)
  • Trustee Prostate Action (2010-2013)

Previous posts:

  • Pathway director, Urological Cancer, UCL Partners, London Cancer ICS (2011 to 2012)
  • Clinical director, Cancer Services UCLH (2009-2011)
  • Clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England (2003-2007)

Specialties

Research interests

  • Prostate cancer
  • Focal therapy
  • Non-invasive diagnosis
  • MRI scan
  • Active surveillance
  • Salvage therapy
  • High intesntivy focused ultrasound
  • Photo-dynamic therapy
  • Vascular targeted therapy
  • Photo therapy
  • Cyrosurgery

Languages spoken

Spanish

Publications

Ten most relevant publications:

Citation metrics (September 2018): 20,033 citations overall. h-Index 73; i10-index 244

  • Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu J, Margolis D, Crouzet S, Klotz L, Taneja S.S, Pinto P , Gill G, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams N, Brew-Graves C, Takwoingi Y, Emberton M, Moore C.M. MRI-Targeted or Transrectal Ultrasonographic Biopsy for Prostate-Cancer Diagnosis. NEJM N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18. PMID:29552975
  • Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20. PMID:28110982
  • Faria R, Soares MO, Spackman E, Ahmed HU, Brown LC, Kaplan R, Emberton M, Sculpher MJ. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. 2018 Jan;73(1):23-30. doi: 10.1016/j.eururo.2017.08.018. Epub 2017 Sep 19. PMID:28935163
  • Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011 Apr;59(4):477-94. doi: 10.1016/j.eururo.2010.12.009. Epub 2010 Dec 21. PMID:21195536
  • Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin P, KirkhamAP, Padhani AR, Persad R, Puech P, Punwani S, Sohaib A, Tombal B, Villers A, Emberton M. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging. 2013 Jan;37(1):48-58. doi: 10.1002/jmri.23689. Epub 2012 May 7. Review. PMID: 22566285
  • Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol. 2006 Dec;50(6):1163-74; discussion 1175. Epub 2006 Jun 30. Review. PMID:16842903
  • Arumainayagam N, Ahmed HU, Moore CM, Freeman A, Allen C, Sohaib SA, Kirkham A, van der Meulen J, Emberton M. Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology. 2013 Sep;268(3):761-9. doi: 10.1148/radiol.13120641. Epub 2013 Apr 5. PMID:23564713
  • Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC, Freeman A, Allen C, Kirkham A, van der Meulen J, Emberton M. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol. 2013 Mar;189(3):860-6. doi: 10.1016/j.juro.2012.10.009. Epub 2012 Oct 11. PMID:23063807
  • Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015 Dec;68(6):1045-53. doi: 10.1016/j.eururo.2015.01.013. Epub 2015 Feb 2. Review. PMID: 25656808
  • Abd-Alazeez M, Kirkham A, Ahmed HU, Arya M, Anastasiadis E, Charman SC, Freeman A, Emberton M. Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):40-6. doi: 10.1038/pcan.2013.43. Epub 2013 Oct 15. PMID:24126797
  • Moore CM, Robertson NL, Jichi F, Damola A, Ambler G, Giganti F, Ridout AJ, Bott SR, Winkler M, Ahmed HU, Arya M, Mitra AV, McCartan N, Freeman A, Jameson C, Castro R, Gambarota G, Whitcher BJ, Allen C, Kirkham A, Emberton M. The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial. J Urol. 2017 Apr;197(4):1006-1013. doi: 10.1016/j.juro.2016.11.090. Epub 2016 Nov 19 PMID:27871928